A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies



Status:Recruiting
Conditions:Neurology, Epilepsy
Therapuetic Areas:Neurology, Other
Healthy:No
Age Range:2 - 17
Updated:2/17/2019
Start Date:August 8, 2018
End Date:April 21, 2021
Contact:Ovid Therapeutics Call Center
Email:clinical@ovidrx.com
Phone:+1-646-661-7661

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies

The purpose of this study is to investigate the efficacy, safety and tolerability of TAK-935
(OV935), compared to placebo, as an adjunctive therapy in pediatric patients with epileptic
seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome (LGS).

The drug being tested in this study is called TAK-935 (OV935). This randomized, double-blind
study will assess the effects of TAK-935 (OV935), compared to placebo, on efficacy, safety,
and tolerability in pediatric patients with Dravet syndrome or LGS. This multi-center trial
will be conducted worldwide and will enroll approximately 126 participants.

Participants will be randomized based on their diagnosis in 2 categories; Dravet syndrome and
LGS. The study will consist of 2 periods: Screening Period and Treatment Period. The overall
duration of Treatment Period is 14 weeks including 2-week Titration Period and 12-week
Maintenance Period. The overall time to participate in this study is approximately 24 weeks.

Participants completing this study will have an option to enroll in the open-label extension
study, under a separate protocol.

Inclusion Criteria:

1. Male and female patients aged ≥2 and ≤17 years

2. Clinical diagnosis of Dravet Syndrome or LGS

3. Weight of ≥10 kg at the Screening visit

4. Currently taking 1 to 4 anti-epileptic drugs (AED) at a stable dose

5. Failed to become and remain seizure free with trials of at least 2 AEDs

Exclusion Criteria:

1. On average 1 or more episodes of convulsive status epilepticus requiring
hospitalization per week in the 3 months immediately prior to the screening visit

2. Non-epileptic events that cannot be reliably distinguished from epileptic seizures

3. Participation in a clinical study involving another study drug in the previous month
We found this trial at
11
sites
Aurora, Colorado 80045
?
mi
from
Aurora, CO
Click here to add this to my saved trials
7485 Sandlake Commons Blvd.
Orlando, Florida 32835
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Atlanta, Georgia 30318
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Beijing,
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Miami, Florida 33155
?
mi
from
Miami, FL
Click here to add this to my saved trials
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
5600 Oakbrook Parkway
Norcross, Georgia 30093
?
mi
from
Norcross, GA
Click here to add this to my saved trials
200 1st Street Southwest
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Winston-Salem, North Carolina 27157
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials